Sandra Delores Collins, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: Rush Central Clinic, 1221 24th Avenue, Meridian, MS 39301 Phone: 601-486-4210 Fax: 601-486-4219 |
Cynthia F. Messer, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 905c S Frontage Rd, Suite C, Meridian, MS 39301 Phone: 601-703-3018 Fax: 601-703-9283 |
Sharon Diedrichsen, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 905c S Frontage Rd, Meridian, MS 39301 Phone: 601-486-4210 Fax: 601-486-4219 |
Jennifer L Johnson, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 905c S Frontage Rd, Meridian, MS 39301 Phone: 601-486-4210 Fax: 601-486-4219 |
Linda I. Mclendon, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 905c S Frontage Rd, Meridian, MS 39301 Phone: 601-486-4210 Fax: 601-486-4219 |
Melissa Bryan, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1020 22nd Ave Ste B, Meridian, MS 39301 Phone: 601-703-1003 |
Cathy G. Williamson, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 905c S Frontage Rd, Meridian, MS 39301 Phone: 601-486-4210 Fax: 601-486-4219 |
Shelley Creighton, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 1020 22nd Ave Ste B, Meridian, MS 39301 Phone: 601-703-1003 Fax: 601-703-0124 |
News Archive
Researchers from Bangalore, India, have found that 68 percent of pre-symptomatic patients with COVID-19 may be shedding the virus and potentially infecting others. Their study titled, "Quantitative COVID-19 infectiousness estimate correlating with viral shedding and culturability suggests 68% pre-symptomatic transmissions," was published on the open-access preprint server Medrxiv.
Medicare patients with poor prognosis cancers who received hospice care had significantly lower rates of hospitalization, intensive care unit (ICU) admissions and invasive procedures at the end of life, along with significantly lower health care expenditures during the last year of life, according to a study in the November 12 issue of JAMA.
Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.
An automated system that identifies high-risk osteoporosis patients being treated for fractures and can generate letters encouraging follow-up is an effective way to promote osteoporosis intervention and prevent future fractures, according to Penn State College of Medicine researchers.
› Verified 7 days ago